Anti-Human ITGB2 Therapeutic Antibody Fab Fragment (Hu23F2G (also known as LeukArrest and Rovelizumab))
This antibody immunologically reacts with the common β chain (CD18) of human leukocyte integrins and/or competes with mAb 60.3 for binding to human LFA-1, which is useful for the alleviation of symptoms associated with inflammatory disease states, and more particularly to the inhibition of inflammatory processes associated with the multiple sclerosis disease.
Supplier | Creative Biolabs |
---|---|
Product # | TAB-1582CL-F(E) |
Pricing | Inquiry |
Type | Humanized antibody |
Host | Human |
Target | CD18 |